This segment focuses on the development of novel therapeutics to treat acute organ injuries, including acute kidney injury (AKI), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), central nervous system injuries, and heart injuries. The lead product candidate in this segment is ANG-3777, a hepatocyte growth factor (HGF) mimetic. Research and development activities involve preclinical studies and clinical trials to evaluate the safety and efficacy of ANG-3777 in improving organ function and reducing inflammation. The segment aims to address the significant unmet medical needs of patients suffering from acute organ injuries, potentially reducing morbidity and mortality. Future opportunities include expanding the indications for ANG-3777 and developing new therapies for other acute organ injuries.

This segment is dedicated to the discovery and development of small molecule therapeutics for fibrotic diseases. The pipeline includes ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitor, and CYP11B2, an aldosterone synthase inhibitor. Research and development efforts are focused on identifying and validating novel targets involved in the pathogenesis of fibrosis. Technologies used include high-throughput screening, medicinal chemistry, and in vivo models of fibrosis. The segment aims to develop therapies that can halt or reverse the progression of fibrotic diseases, improving patient outcomes and quality of life. Future opportunities include expanding the pipeline with new drug candidates and exploring combination therapies.